Potentiators of glutamate receptors

Details Potentiators of glutamate receptors Potentiators of glutamate receptors

2002-11-20

2004-10-05

Davis, Zinna Northington (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S338000

Reexamination Certificate

active

06800651

ABSTRACT:

The present invention provides potentiators of glutamate receptors (compounds of formula I), pharmaceutical compositions thereof, and methods of using the same, processes for preparing the same, and intermediates thereof.
BACKGROUND OF THE INVENTION
The excitatory amino acid L-glutamate (sometimes referred to herein simply as glutamate) through its many receptors mediates most of the excitatory neurotransmission within the mammalian central nervous system (CNS). The excitatory amino acids, including glutamate, are of great physiological importance, playing a role in a variety of physiological processes, such as long-term potentiation (learning and memory), the development of synaptic plasticity, motor control, respiration, cardiovascular regulation, and sensory perception.
Glutamate acts via at least two distinct classes of receptors. One class is composed of the ionotropic glutamate (iGlu) receptors that act as ligand-gated ionic channels. Via activation of the iGlu receptors, glutamate is thought to regulate fast neuronal transmission within the synapse of two connecting neurons in the CNS. The second general type of receptor is the G-protein or second messenger-linked “metabotropic” glutamate (mGlu) receptor. Both types of receptors appear not only to mediate normal synaptic transmission along excitatory pathways, but also participate in the modification of synaptic connections during development and throughout life. Schoepp, Bockaert, and Sladeczek,
Trends in Pharmacol. Sci.,
11, 508 (1990); McDonald and Johnson,
Brain Research Reviews,
15, 41 (1990).
The present invention relates to potentiators of mGlu receptors. The mGlu receptors belong to the Type III G-protein coupled receptor (GPCR) superfamily. This superfamily of GPCR's, including the calcium-sensing receptors, GABA
B
receptors and pheromone receptors, which are unique in that they are activated by binding of effectors to the amino-terminus portion of the receptor protein. The mGlu receptors are thought to mediate glutamate's demonstrated ability to modulate intracellular signal transduction pathways. Ozawa, Kamiya and Tsuzuski,
Prog. Neurobio.,
54, 581 (1998). They have been demonstrated to be localized both pre- and post-synaptically where they can regulate neurotransmitter release, either glutamate or other neurotransmitters, or modify the post-synaptic response of neurotransmitters, respectively.
At present, there are eight distinct mGlu receptors that have been positively identified, cloned, and their sequences reported. These are further subdivided based on their amino acid sequence homology, their ability to effect certain signal transduction mechanisms, and their known pharmacological properties. Ozawa, Kamiya and Tsuzuski,
Prog. Neurobio.,
54, 581 (1998). For instance, the Group I mGlu receptors, which include the mGlu
1
and mGlu
5
, are known to activate phospholipase C (PLC) via G&agr;q-proteins thereby resulting in the increased hydrolysis of phosphoinositides and intracellular calcium mobilization. There are several compounds that are reported to activate the Group I mGlu receptors including DHPG, (R/S)-3,5-dihydroxyphenylglycine. Schoepp, Goldworthy, Johnson, Salhoff and Baker,
J. Neurochem.,
63, 769 (1994); Ito, et al.,
Neurorep.,
3, 1013 (1992). The Group II mGlu receptors consist of the two distinct receptors, mGlu
2
and mGlu
3
receptors. Both have been found to be negatively coupled to adenylate cyclase via activation of G&agr;i-protein. These receptors can be activated by a group-selective compound such as 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate. Monn, et al.,
J. Med. Chem.,
40, 528 (1997); Schoepp, et al.,
Neuropharmacol.,
36, 1 (1997). Similarly, the Group III mGlu receptors, including mGlu
4
, mGlu
6
, mGlu
7
and mGlu
8
, are negatively coupled to adenylate cyclase via G&agr;i and are potently activated by L-AP
4
(L-(+)-2-amino-4-phosphonobutyric acid). Schoepp,
Neurochem. Int.,
24, 439 (1994).
It should be noted that many of the available pharmacological tools are not ideal in that they cross react not only on the receptors within a Group of mGlu receptors but also often have some activity between Groups of mGlu receptors. For instance, compounds such as 1S,3R-ACPD, (1S,3R)-1-aminocyclopentane-trans-1,3-dicarboxylic acid, are believed to activate all of the Group I, II and III mGlu receptors depending upon the dose utilized while others, such as 1S,3S-ACPD, (1S, 3S)-1-aminocyclopentane-trans-1,3-dicarboxylic acid, are more selective for the Group II receptors (mGlu
2/3
) than the Group I (mGlu
1/5
) or Group III (mGlu
4/6/7/8
). Schoepp,
Neurochem. Int.,
24, 439 (1994). To date, there are very few examples of selective agents for the mGlu receptors. Schoepp, Jane, and Monn,
Neuropharmacol.,
38, 1431 (1999).
It has become increasingly clear that there is a link between modulation of excitatory amino acid receptors, including the glutamatergic system, through changes in glutamate release or alteration in postsynaptic receptor activation, and a variety of neurological and psychiatric disorders. e.g. Monaghan, Bridges and Cotman,
Ann. Rev. Pharmacol. Toxicol.,
29, 365-402 (1989); Schoepp and Sacann,
Neurobio. Aging,
15, 261-263 (1994); Meldrum and Garthwaite,
Tr. Pharmacol. Sci.,
11, 379-387 (1990). The medical consequences of such glutamate dysfunction makes the abatement of these neurological processes an important therapeutic goal.
SUMMARY OF THE INVENTION
This invention provides compounds of formula I:
wherein
R
1
is selected from the group consisting of —C(O)R
3
, —C(O)OR
4
, and —SO
2
R
5
 wherein R
3
is selected from the group consisting of alkyl and cycloalkyl, R
4
is selected from the group consisting of alkyl and cycloalkyl, R
5
is selected from the group consisting of alkyl, cycloalkyl, and fluorinated alkyl;
R
2
is from 1 to 3 substituents independently selected from the group consisting of hydrogen, hydroxy, trisubstituted silyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, cycloalkyl, substituted cycloalkyl, halogen, cyano, nitro, phenyl, substituted phenyl, pyridyloxy, thiophenoxy, substituted thiophenoxy, phenylsulfinyl, substituted phenylsulfinyl, phenylsulfonyl, substituted phenylsulfonyl, benzoyl, substituted benzoyl, phenoxy, and substituted phenoxy;
or
two R
2
substituents are taken together, on adjacent positions, to form a fused cycloalkyl or a methylenedioxy ring, and one R
2
substituent is selected from the group consisting of hydrogen, hydroxy, trisubstituted silyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, substituted alkoxy, cycloalkoxy, substituted cycloalkoxy, cycloalkyl, substituted cycloalkyl, halogen, cyano, nitro, phenyl, substituted phenyl, pyridyloxy, thiophenoxy, substituted thiophenoxy, phenylsulfinyl, substituted phenylsulfinyl, phenylsulfonyl, substituted phenylsulfonyl, benzoyl, substituted benzoyl, phenoxy, and substituted phenoxy;
R
6
is from 1 to 2 substituents independently selected from the group consisting of hydrogen, alkyl, alkoxy, trifluoromethyl, halogen, phenoxy, and substituted phenoxy;
X is selected from the group consisting of a bond, —CH
2
—, —CHR
7
—, and —CH
2
CH
2
— wherein R
7
is lower alkyl;
Y is selected from the group consisting of a bond, —CH
2
—, —CHR
8
—, —CH
2
CH
2
—, —CHR
9
CH
2
—, and —CH
2
CHR
9
wherein R
8
is lower alkyl and R
9
is lower alkyl;
and the pharmaceutically acceptable salts thereof and the pyridyl N-oxide thereof.
The present invention also provides for novel pharmaceutical compositions, comprising: a compound of the formula I and a pharmaceutically acceptable diluent.
Because the compounds of formula I enhance the normal physiological function of the mGlu receptors, the compounds of formula I are useful for the treatment of a variety of neurological and psychiatric disorders associated with glutamate dysfunction, including: acute neurological and psychiatric disorders such as cerebral deficits subsequent to cardiac

Affiliated with

Also associated with

Rating

Potentiators of glutamate receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Potentiators of glutamate receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potentiators of glutamate receptors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3308069